Posts by Genevieve M. Boland, MD, PhD
-
Revolutionizing Cancer Immunotherapy for Melanoma and Beyond
Researchers at Massachusetts General Hospital won a Breakthrough Award to enhance personalized approaches to immunotherapy for metastatic melanoma.
-
Making CAR T-Cell Therapy More Effective Against Solid Tumors
A new technique from Massachusetts General Hospital uses disulfiram, copper, and radiation to stress cancer cells/tumors to rejuvenate CAR T-cells and ready the tumor microenvironment for CAR T-cell therapy.
-
37 Biopsies, Nine Years: Mapping Evolution of Resistance to Melanoma Immunotherapy in a Former Complete Responder
Genevieve Boland, MD, PhD, Keith Flaherty, MD, and colleagues analyzed tumor samples over the entire clinical course of a patient with metastatic melanoma, providing insights into tumor microenvironmental changes that occurred when he became resistant to immune checkpoint inhibition after a previous complete response.
Biography
Genevieve M. Boland, MD, PhD, FACS is an Associate Professor of Surgery at Harvard Medical School, Section Head of Melanoma/Sarcoma Surgery, and Surgical Director of the Termeer Center for Targeted Therapies at the Massachusetts General Hospital. Her primary clinical focus is on melanoma and cutaneous oncology.
She undertook combined MD/PhD training, completing a PhD in Cell and Tissue Engineering at the National Institutes of Health focusing on signaling pathways in adult, human mesenchymal stem cells. She graduated cum laude from Thomas Jefferson University as a member of the Alpha Omega Alpha medical honor society and completed her general surgical training at Mass General Hospital. Following this, she completed a clinical fellowship in Complex General Surgical Oncology and a combined research fellowship at the University of Texas MD Anderson Cancer Center. She is focused on the clinical management of skin cancer patients. She is board certified in General Surgery and Complex General Surgical Oncology, and she is a Fellow of the American College of Surgeons.
Dr. Boland has received research support from many groups including the American Surgical Association Foundation Fellowship, the Association of Women Surgeons Research Fellowship, the Harvard Catalyst Medical Research Investigator Training Award, the Karin Grunebaum Cancer Foundation Fellowship, the Society of Surgical Oncology, the Melanoma Research Foundation Breakthrough Consortium, the National Institutes of Health, and the Department of Defense. She is Director of the Surgical Oncology Research Laboratories and Director of the Therapeutic Intralesional Program where she is building a portfolio of direct-to-tumor therapies across multiple tumor types. She is also an Associate Member of the Broad Institute of MIT and Harvard. Her laboratory is currently focused on molecular profiling of melanoma, characterization of molecular and immunological changes that occur during immunotherapy, and the identification of circulating biomarkers of cancer.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
